Biotech Concert Pharmaceuticals files for a $75 million IPO

Comment

Shutterstock photo

Concert Pharmaceuticals, which is developing novel small molecule drugs for the treatment of spasticity and diabetic kidney disease, filed on Monday with the SEC to raise up to $75 million in an initial public offering. The Lexington, MA-based company, which was founded in 2006 and booked $24 million in license and milestone revenue for the 12 months ended September 30, 2013, plans to list on the NASDAQ under the symbol CNCE. UBS Investment Bank and Wells Fargo Securities are the joint bookrunners on the deal. No pricing terms were disclosed.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.



This article appears in: News Headlines IPOs
Referenced Stocks:


More from Renaissance Capital

Subscribe






Renaissance Capital
Contributor:

Renaissance Capital

IPOs
Follow on:


Find a Credit Card

Select a credit card product by:
Select an offer:
Search
Data Provided by BankRate.com